WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H462443
CAS#: 1628428-01-2
Description: PKR-IN-2 is a pyruvate kinase (PKR) activator.
Hodoodo Cat#: H462443
Name: PKR-IN-2
CAS#: 1628428-01-2
Chemical Formula: C24H28N4O4S
Exact Mass: 468.18
Molecular Weight: 468.572
Elemental Analysis: C, 61.52; H, 6.02; N, 11.96; O, 13.66; S, 6.84
Synonym: PKR-IN-2; PKR IN 2; PKR IN-2; PKR-IN 2
IUPAC/Chemical Name: N-(4-(4-hydroxy-4-isobutylpiperidine-1-carbonyl)phenyl)quinoxaline-5-sulfonamide
InChi Key: JTGUGSWLWPKCGF-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H28N4O4S/c1-17(2)16-24(30)10-14-28(15-11-24)23(29)18-6-8-19(9-7-18)27-33(31,32)21-5-3-4-20-22(21)26-13-12-25-20/h3-9,12-13,17,27,30H,10-11,14-16H2,1-2H3
SMILES Code: O=C(N1CCC(CC(C)C)(O)CC1)C2=CC=C(NS(C3=C(N=CC=N4)C4=CC=C3)(=O)=O)C=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 468.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Popovici-Muller, et al. Preparation of N-(piperidinecarbonylphenyl) sulfonamide compounds as pyruvate kinase modulators. From PCT Int. Appl. (2014), WO2014139144A1 20140918.
2: Cianchetta Giovanni, et al. Preparation of aroylpiperidines, particularly arysulfonylamino and heteroarylsulfonylamino substituted, as pyruvate kinase PKM2 modulators useful in the treatment of cancer and compositions containing them. From PCT Int. Appl.